

K113588

FEB 22 2012

**510(k) Summary for the
Lutronic Corporation Spectra Laser System**

This 510(k) Summary is being submitted in accordance with the requirements of the SMDA 1990 and 21 CFR 807.92.

1. General Information

Submitter: Lutronic Corporation
Room 403-1,2,3,4,5, 404 Ilsan Technotown
1141-1, Baekseok-dong, Ilsandong-gu,
Goyang-si, Gyeonggi-do, 410-722
Republic of Korea

Contact Person: Jhung Won Vojir, Ph.D
Chief Executive Officer
Lutronic, Inc.
Six Neshaminy Interplex, Suite
Trevose, PA 19053
Telephone: 215-205-2219
Fax: 609-488-6958

Summary Preparation Date: December 2, 2011

2. Names

Device Name: SPECTRA Q-Switched Nd:YAG
Laser System with Dye Handpieces

Classification Name: Laser Instrument, Surgical, Powered
Product Code: GEX
Panel: General & Plastic Surgery

3. Predicate Devices

The SPECTRA Laser System is substantially equivalent to the Lutronic Corporation SPECTRA Laser System (K103455) and Palomar Medical Technologies, Inc. Q-YAG 5 (K061436).

4. Device Description

The SPECTRA Laser System produces a pulsed beam of coherent near infrared (1064 nm) and visible (532nm) light. This beam is directed to the treatment zone by means of an articulated arm coupled to a handpiece. In addition, two dye

handpieces are available that convert the 532 nm wavelength to 585 nm and 650 nm.

When the beam contacts human tissue, the energy in the beam is absorbed, resulting in a very rapid, highly localized temperature increase to the target chromospheres such as melanin and tattoo particles. This increases localized temperature of the chromospheres. The instantaneous temperature increase causes fragmentation of the chromospheres to smaller particles.

By directing the beam onto specific tissue locations, using different handpieces, and controlling the treatment fluence, the intensity of the temperature of the target can be varied. The physician can optimize the effect for different applications by controlling the energy of the laser pulse and the spot size of the treatment beam.

5. Indications for Use

The SPECTRA Laser System is indicated for the incision, excision, ablation, vaporization of soft tissues for general dermatology, dermatologic and general surgical procedures for coagulation and hemostasis.

532nm Wavelength (nominal delivered energy of 585 nm and 650 nm with optional dye handpieces):

- Tattoo removal: light ink (red, tan, purple, orange, sky blue, green)
- Removal of Epidermal Pigmented Lesions
- Removal of Minor Vascular Lesions including but not limited to telangiectasias
- Treatment of Lentigines
- Treatment of Café-Au-Lait
- Treatment of Seborrheic Keratoses
- Treatment of Post Inflammatory Hyper-Pigmentation
- Treatment of Becker's Nevi, Freckles and Nevi Spilus

1064nm Wavelength:

- Tattoo removal: dark ink (black, blue and brown)
- Removal of Nevus of Ota
- Removal or lightening of unwanted hair with or without adjuvant preparation.
- Treatment of Common Nevi
- Skin resurfacing procedures for the treatment of acne scars and wrinkle
- Treatment of melasma.

6. Substantial Equivalence

The SPECTRA Laser System is substantially equivalent to the SPECTRA Laser System cleared in K103455 and the Palomar Q-YAG 5 Laser System cleared in K061436. The SPECTRA Laser System has the same indications statement as the

SPECTRA Laser System cleared in K103455 with the exception of the melasma indication for use which is being added for the 1064 nm wavelength in this 510(k). The SPECTRA Laser System has the same intended use as the Palomar Q-YAG 5 (K061436) with minor differences in the indications for use statement. Both the SPECTRA and the Palomar Q-YAG 5 are intended for the incision, excision, ablation, and vaporization of soft tissues for general dermatology, dermatologic and general surgical procedures for coagulation and hemostasis. The SPECTRA Laser System has the same technological characteristics as the predicate devices. All three devices are Q-switched Nd:YAG lasers operating at wavelength of 1064 nm and 532 nm. Additionally, all three devices have dye handpieces that convert the 532 nm wavelength beam into 585 nm or 650 nm wavelengths. The SPECTRA Laser System has the exact technological characteristics as the previously cleared SPECTRA Laser System (K103455). The SPECTRA Laser System has similar technological characteristics to the Q-YAG 5 predicate. The SPECTRA Laser System is substantially equivalent to the predicate devices.

7. Performance Data

None presented.



Food and Drug Administration
10903 New Hampshire Avenue
Document Control Room - WO66-G609
Silver Spring, MD 20993-0002

FEB 22 2012

Lutronic Corporation
% Lutronic, Inc.
Jhung Won Vojir
6 Neshaminy Interplex, Suite 207
Trevose, Pennsylvania 19053

Re: K113588

Trade/Device Name: SPECTRA Laser System

Regulation Number: 21 CFR 878.4810

Regulation Name: Laser surgical instrument for use in general and plastic surgery and
in dermatology

Regulatory Class: II

Product Code: GEX

Dated: December 2, 2012

Received: December 5, 2012

Dear Jhung Won Vojir:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act

or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,



Mark N. Melkerson
Director
Division of Surgical, Orthopedic
and Restorative Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Indications for Use

510(k) Number (if known): K 11 3588

Device Name: SPECTRA Laser System

Indications for Use:

The SPECTRA Laser System is indicated for: the incision, excision, ablation, vaporization of soft tissues for general dermatology, dermatologic and general surgical procedures for coagulation and hemostasis.

532nm Wavelength (nominal delivered energy of 585 nm and 650 nm with optional dye handpieces):

- Tattoo removal: light ink (red, tan, purple, orange, sky blue, green)
- Removal of Epidermal Pigmented Lesions
- Removal of Minor Vascular Lesions including but not limited to telangiectasias
- Treatment of Lentigines
- Treatment of Café-Au-Lait
- Treatment of Seborrheic Keratoses
- Treatment of Post Inflammatory Hyper-Pigmentation
- Treatment of Becker's Nevi, Freckles and Nevi Spilus

1064nm Wavelength:

- Tattoo removal: dark ink (black, blue and brown)
- Removal of Nevus of Ota
- Removal or lightening of unwanted hair with or without adjuvant preparation.
- Treatment of Common Nevi
- Skin resurfacing procedures for the treatment of acne scars and wrinkle
- Treatment of melasma

Prescription Use X
(Part 21 CFR 801 Subpart D)

AND/OR

Over The Counter Use _____
(Part 21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Niraj Patel for MxM Page 1 of 1
 (Division Sign-Off)
 Division of Surgical, Orthopedic,
 and Restorative Devices

510(k) Number K113588